XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.1

Note 2 - Revenue (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Disaggregation of Revenue [Table Text Block]

		Three Months Ended
		March 31,
		2022				2021
Product sales, net:
ORLADEYO		$	49,386			$	10,938
RAPIVAB			160				113
Peramivir			—				6,820
Total product sales, net			49,546				17,871
Royalty revenue			347				(897	)
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services			30				2,085
Total collaborative and other research and development revenues			30				2,085
Total revenues		$	49,923			$	19,059

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration